Ken Griffin I Mab Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.03 - $1.72 $55,002 - $91,848	53,400 Added 1780.0%	56,400 $69,000
Q2 2024 Aug 14, 2024	SELL	$1.58 - $1.9 $14,062 - $16,910	-8,900 Reduced 74.79%	3,000 $5,000
Q1 2024 May 15, 2024	BUY	$1.54 - $2.37 $17,556 - $27,018	11,400 Added 2280.0%	11,900 $22,000
Q4 2023 Feb 14, 2024	SELL	$1.21 - $1.9 $9,559 - $15,010	-7,900 Reduced 94.05%	500 $0
Q3 2023 Nov 14, 2023	SELL	$1.18 - $3.06 $1,534 - $3,978	-1,300 Reduced 13.4%	8,400 $11,000
Q2 2023 Aug 14, 2023	SELL	$2.95 - $3.85 $8,260 - $10,780	-2,800 Reduced 22.4%	9,700 $29,000
Q1 2023 May 15, 2023	SELL	$3.08 - $7.39 $17,248 - $41,384	-5,600 Reduced 30.94%	12,500 $43,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $4.86 $23,184 - $34,992	7,200 Added 66.06%	18,100 $75,000
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $47,318 - $145,612	-11,800 Reduced 51.98%	10,900 $44,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.